| Literature DB >> 35550691 |
A John Camm1, Gerald V Naccarelli2, Suneet Mittal3, Harry J G M Crijns4, Stefan H Hohnloser5, Chang-Sheng Ma6, Andrea Natale7, Mintu P Turakhia8, Paulus Kirchhof9.
Abstract
The considerable mortality and morbidity associated with atrial fibrillation (AF) pose a substantial burden on patients and health care services. Although the management of AF historically focused on decreasing AF recurrence, it evolved over time in favor of rate control. Recently, more emphasis has been placed on reducing adverse cardiovascular outcomes using rhythm control, generally by using safe and effective rhythm-control therapies (typically antiarrhythmic drugs and/or AF ablation). Evidence increasingly supports early rhythm control in patients with AF that has not become long-standing, but current clinical practice and guidelines do not yet fully reflect this change. Early rhythm control may effectively reduce irreversible atrial remodeling and prevent AF-related deaths, heart failure, and strokes in high-risk patients. It has the potential to halt progression and potentially save patients from years of symptomatic AF; therefore, it should be offered more widely.Entities:
Keywords: antiarrhythmic drugs; atrial fibrillation progression; catheter ablation; early intervention; new-onset atrial fibrillation; paroxysmal atrial fibrillation
Mesh:
Substances:
Year: 2022 PMID: 35550691 DOI: 10.1016/j.jacc.2022.03.337
Source DB: PubMed Journal: J Am Coll Cardiol ISSN: 0735-1097 Impact factor: 24.094